Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis.

Autor: Tutrone R; Chesapeake Urology Research Associates, Baltimore, MD, USA. rtutrone@uniteduro.com., Lowentritt B; Chesapeake Urology Research Associates, Baltimore, MD, USA., Neuman B; Chesapeake Urology Research Associates, Baltimore, MD, USA., Donovan MJ; Icahn School of Medicine at Mt. Sinai, New York City, NY, USA., Hallmark E; Exosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA., Cole TJ; Exosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA., Yao Y; Exosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA., Biesecker C; Chesapeake Urology Research Associates, Baltimore, MD, USA., Kumar S; Exosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA., Verma V; Exosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA., Sant GR; Exosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA.; Department of Urology, Tufts University, Medford, MA, USA., Alter J; Exosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA., Skog J; Exosome Diagnostics, a Bio-Techne Brand, Waltham, MA, USA.
Jazyk: angličtina
Zdroj: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2024 Mar; Vol. 27 (1), pp. 161.
DOI: 10.1038/s41391-023-00681-3
Databáze: MEDLINE